Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

Oxford, UK – December 24 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announces a strategic partnership with RwHealth for “SENSIGHT” Sensyne’s real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a “SENSIGHT Channel Partner” with the right to offer SENSIGHT to its customers.

December 24, 2021

London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform.” 

Orlando Agrippa, CEO and founder of RwHealth added: 

“Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.

Press release

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

December 24, 2021
Oxford, UK – December 24 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announces a strategic partnership with RwHealth for “SENSIGHT” Sensyne’s real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a “SENSIGHT Channel Partner” with the right to offer SENSIGHT to its customers.

London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform.” 

Orlando Agrippa, CEO and founder of RwHealth added: 

“Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.

Press release

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

December 24, 2021
Oxford, UK – December 24 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announces a strategic partnership with RwHealth for “SENSIGHT” Sensyne’s real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a “SENSIGHT Channel Partner” with the right to offer SENSIGHT to its customers.

London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform.” 

Orlando Agrippa, CEO and founder of RwHealth added: 

“Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.

Press release

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

Oxford, UK – December 24 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announces a strategic partnership with RwHealth for “SENSIGHT” Sensyne’s real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a “SENSIGHT Channel Partner” with the right to offer SENSIGHT to its customers.

London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform.” 

Orlando Agrippa, CEO and founder of RwHealth added: 

“Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.

Arrange to meet us
Press release

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

December 24, 2021
Oxford, UK – December 24 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announces a strategic partnership with RwHealth for “SENSIGHT” Sensyne’s real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a “SENSIGHT Channel Partner” with the right to offer SENSIGHT to its customers.

London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform.” 

Orlando Agrippa, CEO and founder of RwHealth added: 

“Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.